Oğuz KARAHAN, Orkut GÜÇLÜ, Süleyman YAZICI, Bekir YILDIZ, Ahmet ÇALIŞKAN, Celal YAVUZ, Sinan DEMİRTAŞ, Orhan TEZCAN

İndüklenebilir periferik iskeminin saptanmasında C-tip natriüretik peptidin gösterge olarak kullanımı

Amaç: Bu deneysel çalışmada, periferik iskeminin başında kritik saatlerdeki plazma C-tip natriüretik peptid (CNP) düzeylerindeki değişiklikler değerlendirildi.Çalışma planı: Çalışmaya 40 adet Sprague-Dawley cinsi erkek sıçan (8-12 haftalık ve ortalama ağırlıkları 230±30 g) alındı. Her grupta 10 sıçan olacak şekilde dört grup oluşturuldu: kontrol grubu, grup 1, grup 2 ve grup 3. Kontrol grubunda herhangi bir işlem yapılmadan başlangıç plazma CNP değeri tespit edilirken, grup 1'de periferik iskeminin ikinci saatinde plazma CNP düzeyine bakıldı. Grup 2'de periferik iskeminin beşinci saatindeki plazma CNP düzeyi tespit edilirken, plazma CNP düzeyleri grup 3'te periferik iskeminin sekizinci saatinde belirlendi.Bul gu lar: Başlangıç plazma CNP düzeyi kontrol grubunda 0.285±0.011 pmol/L olarak tespit edildi. Periferik iskemi oluşturulan sıçanlarda, plazma CNP düzeyinin zamana bağlı olarak anlamlı olarak arttığı tespit edildi (p

Use of C-type natriuretic peptide as an indicator in detection of inducible peripheral ischemia

Background: In this experimental study, alterations in plasma C-type natriuretic peptide (CNP) levels were evaluated during the critical initial hours of peripheral ischemia. Methods: Forty male Sprague-Dawley type rats (aged 8 to 12 weeks, weighing 230±30 g) were included in the study. Four groups were created with 10 rats namely control group, group 1, group 2, and group 3. Baseline plasma CNP levels were detected in the control group without any intervention, while the plasma CNP levels were determined in the second hour of peripheral ischemia in group 1. Plasma CNP levels were determined in the fifth hour of peripheral ischemia for group 2, whereas plasma CNP levels were determined in group 3 at the eighth hour of peripheral ischemia. Results: The baseline plasma CNP levels were 0.285±0.011 pmol/L in the control group. In rats with peripheral ischemia, a significant time-dependent increase was detected in plasma levels of CNP (p

PDF

___

1. Cargill RI, Barr CS, Coutie WJ, Struthers AD, Lipworth BJ. C-type natriuretic peptide levels in cor pulmonale and in congestive heart failure. Thorax 1994;49:1247-9.
2. Del Ry S, Passino C, Maltinti M, Emdin M, Giannessi D. C-type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severity. Eur J Heart Fail 2005;7:1145-8.
3. Dickey DM, Flora DR, Bryan PM, Xu X, Chen Y, Potter LR. Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the predominant natriuretic peptide receptor in the failing heart. Endocrinology 2007;148:3518-22.
4. Swärd K, Valsson F, Odencrants P, Samuelsson O, Ricksten SE. Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial. Crit Care Med 2004;32:1310-5.
5. Staub D, Nusbaumer C, Zellweger MJ, Jonas N, Wild D, Pfisterer ME, et al. Use of B-type natriuretic peptide in the detection of myocardial ischemia. Am Heart J 2006;151:1223- 30.
6. Nadir MA, Witham MD, Szwejkowski BR, Struthers AD. Meta-analysis of B-type natriuretic peptide's ability to identify stress induced myocardial ischemia. Am J Cardiol 2011;107:662-7.
7. Kumakura H, Kanai H, Araki Y, Hojo Y, Kasama S, Sumino H, et al. Differences in brain natriuretic peptide and other factors between japanese peripheral arterial disease patients with critical limb ischemia and intermittent claudication. J Atheroscler Thromb 2013;20:798-806.
8. Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation 2010;121:2592-600.
9. Birnbaum Y, Hale SL, Kloner RA. Ischemic preconditioning at a distance: reduction of myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of the gastrocnemius muscle in the rabbit. Circulation 1997;96:1641-6.
10. Akar H, Saraç A, Konuralp C, Yildiz L, Kolbakir F. Comparison of histopathologic effects of carnitine and ascorbic acid on reperfusion injury. Eur J Cardiothorac Surg 2001;19:500-6.
11. Yavuz C, Güçlü O, Demirtaş S, Karahan O, Yazıcı S, Çalışkan A, et al. Can elevated prolidase activity predict the duration of ischemic exposure in different types of ischemia? Turk Gogus Kalp Dama 2013;21:1000-1004.
12. Kelsall CJ, Chester AH, Amrani M, Singer DR. C-type natriuretic peptide relaxes human coronary artery bypass grafts preconstricted by endothelin-1. Ann Thorac Surg 2005;80:1347-51.
13. Takahashi T, Allen PD, Izumo S. Expression of A-, B-, and C-type natriuretic peptide genes in failing and developing human ventricles. Correlation with expression of the Ca(2+)- ATPase gene. Circ Res 1992;71:9-17.
14. Scotland RS, Cohen M, Foster P, Lovell M, Mathur A, Ahluwalia A, et al. C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression. Proc Natl Acad Sci U S A 2005;102:14452-7.
15. Alqasim A. Lower level of eNOS and C-type natriuretic peptide in patients with isolated systolic hypertension. Pak J Physiol 2012;8:7-11.
16. Costa MA, Elesgaray R, Caniffi C, Fellet A, Arranz C. Role of cardiovascular nitric oxide system in C-type natriuretic peptide effects. Biochem Biophys Res Commun 2007;359:180-6.
17. Caniffi C, Elesgaray R, Gironacci M, Arranz C, Costa MA. C-type natriuretic peptide effects on cardiovascular nitric oxide system in spontaneously hypertensive rats. Peptides 2010;31:1309-18.
18. Singh HS, Bibbins-Domingo K, Ali S, Wu AH, Schiller NB, Whooley MA. N-terminal pro-B-type natriuretic peptide and inducible ischemia in the Heart and Soul Study. Clin Cardiol 2009;32:447-53. doi: 10.1002/clc.20569.
19. Montagnana M, Lippi G, Fava C, Minuz P, Santonastaso CL, Arosio E, et al. Ischemia-modified albumin and NT-prohormone-brain natriuretic peptide in peripheral arterial disease. Clin Chem Lab Med 2006;44:207-12.20
. Tokudome T, Kishimoto I, Yamahara K, Osaki T, Minamino N, Horio T, et al. Impaired recovery of blood flow after hind-limb ischemia in mice lacking guanylyl cyclase-A, a receptor for atrial and brain natriuretic peptides. Arterioscler Thromb Vasc Biol 2009;29:1516-21.
21. Park K, Itoh H, Yamahara K, Sone M, Miyashita K, Oyamada N, et al. Therapeutic potential of atrial natriuretic peptide administration on peripheral arterial diseases. Endocrinology 2008;149:483-91.
22. Priviero FB, Webb RC. Heme-dependent and independent soluble guanylate cyclase activators and vasodilation. J Cardiovasc Pharmacol 2010;56:229-33.
23. Schulz S. C-type natriuretic peptide and guanylyl cyclase B receptor. Peptides 2005;26:1024-34.
24. Passino C, Del Ry S, Severino S, Gabutti A, Prontera C, Clerico A, et al. C-type natriuretic peptide expression in patients with chronic heart failure: effects of aerobic training. Eur J Cardiovasc Prev Rehabil 2008;15:168-72.